The Prostate Cancer Blog for Wives and Partners lets you know when new information has been added to our site. Anytime a new page is created—or we feel there is something worth noting—it will be posted here.
Advances in genomic sequencing have allowed biomedical companies to develop personalized treatments for a number of diseases. Now a new study from the Mayo Clinic will use genomic sequencing to develop customized treatments for men whose cancer does not respond to hormonal therapy (called castration-resistant prostate cancer). The Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) study will seek to match new targeted drugs with the genomic characteristics of a man’s prostate cancer tumor. Men who are interested in enrolling in the study can call 507-284-3067 for further information. December 3, 2013
In September, researchers from the SELECT trial (Brasky et al) warned that men with high levels of fish oil in their blood had an increased risk of developing a more aggressive form of prostate cancer. Now a new study by researchers at UCLA reports that men with prostate cancer who followed a low-fat diet and took fish oil supplements (5 grams per day in 5 capsules) had lower levels of pro-inflammatory substances in their blood and a lower cell cycle progression (a measure to help predict cancer recurrence). These results suggest that a low-fat diet and fish oil can actually change prostate cancer tissue, which may help prevent aggressive disease. December 3, 2013
A history of infection, previous abdominal surgery, radiation treatment, an enlarged prostate, and prior transurethral resection of the prostate (known as TURP) have been identified as warning signs for potential injury to the urethra during robotic prostatectomies, according to a study published in the Journal of Endourology. Researchers followed 6,442 men who underwent robotic prostatectomy from 2001 to 2013. While the rate of cutting the urethra was only 0.046%, this information may help prevent future injuries. December 1, 2013.
Sexual intimacy is possible despite impotence after prostate cancer treatment. Read our interview with Ralph and Barbara Alterowitz, authors of "Intimacy with Impotence."
Men who are of healthy weight are more likely to survive prostate cancer than men who are overweight or obese when they are diagnosed, according to a Kaiser Permanente study of 751 men with prostate cancer who had radical prostatectomy that was published in the journal of Obesity Research & Clinical Practice. Researchers also found an even stronger correlation between obesity and mortality (death) in men who had more aggressive prostate cancer (Gleason scores of 8 or higher). Men who died from prostate cancer were 50% more likely to be overweight or obese when they were diagnosed compared to men who did not die from the disease. What is unclear is whether the men’s deaths were related to other health problems caused by obesity. We would also like to see more studies to determine whether diet and exercise after after a prostate cancer diagnosis can help a man live longer. October 31, 2013.
Doctor Jo-an Baldwin Peters was kind enough to send us a complimentary copy of her new book: “Prostate Cancer Sexuality Survey Results, Survivor & Partner,” which was a joint project between her and Dr. Joel Funk and Court Brooker, who is a prostate cancer survivor. The book provides charts, tables, and comments that were complied from an online survey that was completed by 448 prostate cancer survivors and 193 partners. One of their findings, which we always stress here, is that there is sexual recovery after prostate cancer, but it takes time. October 29, 2013.
Long-term hormonal therapy after radiation therapy did not improve overall survival in men with intermediate-risk prostate cancer, according to results of a secondary analysis of the RTOG 902 prostate cancer trial, which were presented at the American Society for Radiation Oncology’s 55th Annual Meeting. Researchers determined that there were no additional benefits of long-term hormonal therapy compared to short-term hormonal therapy. You can read the abstract here. October 8, 2013.
Movember 1 is the official start of Movember, a day to shave down and get excited about the hairy month ahead. As the official rules of Movember state, men must begin clean-shaven on the 1st of Movember and grow just a moustache for the 30 days of the month. Learn how you can become a Mo Bro or Mo Sista and join the good fight for men’s health, including prostate cancer here. October 8, 2013.
The Dominion Group, an independent healthcare consulting company, is conducting a nationwide opinion research study to better understand men's experiences with treatment for prostate cancer. This research is currently being conducted with men who are taking Zytiga (abiraterone) to treat their prostate cancer.
New research suggests that a popular type 2 diabetes drug called Metformin may reduce the risk of dying from prostate cancer, as reported by HealthDay News. In a study of nearly 4,000 men with diabetes, those men who were using the drug when they were diagnosed with prostate cancer (median of 19 months) were less likely to die of cancer than men who were taking other diabetes drugs. But researchers need to determine if the drug will work against prostate cancer in men who do not have diabetes. The study was published August 5th in the Journal of Clinical Oncology. August 6, 2013.
Eating a modest amount of walnuts a day helped protect against prostate cancer in an animal study, according to researchers from the School of Medicine at the University of Texas Health Science Center San Antonio. Researchers injected human prostate cancer cells into two groups of mice. One group was fed walnuts that were equivalent to a human eating two handfuls a day. Only 3 of the 16 mice that ate walnuts developed prostate tumors compared to 14 of 32 mice that were not fed walnuts. The tumors that did develop in the walnut-eating group of mice were also smaller. August 1, 2013.
While we know of one radiation oncologist who recommends soy milk to all his advanced prostate cancer patients, Bosland et al have published results of a study in the July 10, 2013 issue of JAMA that demonstrated that men at high risk of PSA failure who consumed a beverage powder supplement containing soy protein isolate every day for 2 years following radical prostatectomy did not experience reduced biochemical recurrence of prostate cancer compared to men who took placebo. This was the first randomized study of soy with cancer as the endpoint and the trial was stopped early for lack of treatment effects. July 16, 2013.
Active surveillance, or watching and waiting, may put African-American men who are diagnosed with very-low-risk prostate cancers at greater risk because they are more likely to have aggressive disease that goes unrecognized with current diagnostic approaches than white men, according to a Johns Hopkins study of more than 1,800 men (1,473 white and 256 African-American) aged 52 to 62, which was published online ahead of the print version in the Journal of Clinical Oncology. The study also demonstrated that the rate of increased pathologic risk was significantly higher in African-Americans (14.8 percent vs. 6.9 percent). All of the men whose records were analyzed were selected from a group of 19,142 men who had surgery between 1992 and 2012 to remove the prostate gland and some of the tissue around it. July 9, 2012.
Eating a healthy diet and getting regular exercise may decrease the risk of aggressive prostate cancer, according to a ScienceDaily report about a study of 2,212 men aged 40 to 70 who were newly diagnosed with prostate cancer. Adhering to four of the eight World Cancer Research Fund (WCRF) lifestyle recommendations predicted a 38% increased risk of aggressive tumors compared to adhering to four or more recommendations. Most notably, eating less than 500 grams (about 17.6 ounces) of red meat per week or less than 125 total kilocalories (1 kilocalorie equals 1,000 calories) per 100 grams (3.5 ounces) of food per day were statistically significantly protective against highly aggressive tumors for all subjects in the study. Prostate cancer aggressiveness was measured using Gleason scores, PSA levels, and the TNM cancer staging system. The study was led by researchers at UCLA's Jonsson Comprehensive Cancer Center and was published online ahead of the print version of the Journal of Cancer and Nutrition. Click on the link below to see all eight WCRF recommendations. July 8, 2013.
The U.S. Food and Drug Administration (FDA) has approved Xofigo® (radium 223 dichloride) for the treatment of men with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease (prostate cancer in the organs in the cavities of the body), according to Bayer HealthCare. Xofigo is the first alpha particle-emitting radioactive therapeutic agent approved by the FDA that demonstrated improvement in overall survival and delay in time to first symptomatic skeletal event compared to placebo in the Phase III ALSYMPCA trial. The first doses are expected to be ready in a few weeks. May 30, 2013.
Discuss information from this website with a medical professional